<?xml version="1.0" encoding="UTF-8"?><rss version="2.0">
<channel>
  <title>Nyheter om: Curasight</title>
  <link>https://www.pressen.se/</link>
  <description>På Pressen.se kan du söka efter artiklar i svenska medier.</description>
    <pubDate>Thu, 21 Nov 2024 06:46:47 GMT</pubDate>
  <item>
    <title>Curasights rörelseförlust minskar</title>
    <pubDate>Thu, 21 Nov 2024 06:46:47 GMT</pubDate>
    <link>https://www.pressen.se/1099115451.html</link>
    <description>Det danska forsknings- och diagnostikbolaget Curasight, noterat på Spotlight, redovisar ett rörelseresultat för det tredje kvartalet 2024 på -8,1 miljoner danska kronor (-8,5)..</description>
    <source>DI</source>
  </item>


  <item>
    <title>Curasight redovisar större förlust</title>
    <pubDate>Thu, 22 Aug 2024 06:54:04 GMT</pubDate>
    <link>https://www.pressen.se/1065202350.html</link>
    <description>Det danska forsknings- och diagnostikbolaget Curasight, noterat på Spotlight, redovisar ett rörelseresultat på -11,0 miljoner danska kronor (-10,7)..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague</title>
    <pubDate>Thu, 14 Sep 2023 15:20:00 GMT</pubDate>
    <link>https://www.pressen.se/928842143.html</link>
    <description>Oral presentation gives more details from the Phase II data where topline results were released on June 29, 2023. Investigators for the Phase II trial concluded that: The majority of the glioma patients displayed uPAR-positive tumors High uPAR expression is significantly correlated with a worse outcome The study demonstrates the potential of uPAR-targeted radionuclide therapy (uTREAT®) for patients with high-grade gliomas Copenhagen, Denmark, September 14, 2023 - Curasight A/S (&quot;Curasight&quot; or the “Company&quot; - TICKER: CURAS) announces today that the previously announced results from the investigator-initiated phase II study using uPAR-PET (uTRACE®) in primary brain cancer have been presented in an oral presentation at the World Molecular Imaging Congress (WMIC) 2023 in Prague..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Curasight and Curium announce global partnership for uTRACE[®] in prostate cancer</title>
    <pubDate>Mon, 01 May 2023 15:20:00 GMT</pubDate>
    <link>https://www.pressen.se/819711194.html</link>
    <description>Curasight to develop its proprietary uTRACE® PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsible for manufacturing and commercialization Curasight eligible for up to USD 70 mn in development and commercial milestones as well as double-digit royalties on sales on eventual commercialization The agreement supports Curasight’s strategy to leverage partnerships as it progresses its uPAR theranostic solution to diagnose and treat certain types of cancer.</description>
    <source>DI</source>
  </item>
  <item>
    <title>Curasight ökar förlusten</title>
    <pubDate>Tue, 24 May 2022 05:07:03 GMT</pubDate>
    <link>https://www.pressen.se/500047124.html</link>
    <description></description>
    <source>DI</source>
  </item>
  <item>
    <title>Curasight utökade förlusten andra kvartalet</title>
    <pubDate>Tue, 24 Aug 2021 05:24:06 GMT</pubDate>
    <link>https://www.pressen.se/181000916.html</link>
    <description></description>
    <source>DI</source>
  </item>
  <item>
    <title>Curasight rapporterar förlust i första kvartalet</title>
    <pubDate>Thu, 20 May 2021 05:50:05 GMT</pubDate>
    <link>https://www.pressen.se/63954578.html</link>
    <description></description>
    <source>DI</source>
  </item>
  <item>
    <title>Curasight is awarded two prizes in Best IPO 2020 by the independent IPO Guide</title>
    <pubDate>Mon, 17 May 2021 05:00:00 GMT</pubDate>
    <link>https://www.pressen.se/60222280.html</link>
    <description></description>
    <source>DI</source>
  </item>
  <item>
    <title>Trading Direkt: Därför kan Husqvarnas dubblas</title>
    <pubDate>Tue, 08 Dec 2020 11:39:11 GMT</pubDate>
    <link>https://www.pressen.se/11916717.html</link>
    <description> 
Bolag som Fredrik Skoglund nämner i intervjun: Husqvarna, PEAB, JM, Sinch, Embracer, Stillfront
Teknisk analys av Tobbe Rosén i tisdagens program: S&amp;P500, OMXS30, DAX, USD/SEK, EUR/SEK, GBP/SEK, Guld, Silver, Koppar, Olja (Brent), AAC, Assa Abloy, Avance Gas Holding, Apple, Neonode, Gränges, Intrum, Addife, Björn Borg, Curasight, Optifreeze, Sdiptech, Intervacc, BW LPG.
 .</description>
    <source>PrivataAffärer</source>
  </item>
</channel>
</rss><!-- CR: cache is set: Sidan laddades på 0.094895124435425 s -->